COM701 shows antitumor activity in advanced solid tumors

COM701, a novel first-in-class immune checkpoint inhibitor, demonstrated antitumor activity alone and in combination with nivolumab among patients with advanced solid tumors, according to results of a phase 1 study presented at the virtual American Association for Cancer Research Annual Meeting.The agent also induced objective responses with and without nivolumab (Opdivo, Bristol-Myers Squibb) in difficult-to-treat tumor types, such as primary peritoneal and microsatellite stable colorectal cancer.“Remarkable advances in antitumor activity have been made during the past several years.Read More